www.ccmjournal.org January 2013 • Volume 41 • Number 1 arachidonic acid. There is interest in the supplementation of parenteral lipid emulsions with ω-3 FA, as eicosanoids derived from ω-3 FA are less inflammatory, inactive, or even anti-inflammatory (3) . Thus, ω-3 FA supplemented parenteral nutrition (PN), if required, could act to dampen the hyperinflammatory state that defines the SIRS, and improve patient outcomes (4) .
Meta-analysis has suggested that ω-3 FA supplemented PN following elective surgery significantly reduced the risk of postoperative infections and shortened intensive therapy unit (ITU) and hospital length of stay (LOS) (5, 6) . Hypothesis-formulating work by Heller and colleagues demonstrated a doseresponse effect of ω-3 FA supplemented PN in a large cohort of critically ill patients, with significant reductions in mortality, antibiotic use, and hospital LOS (4, 7) .
As such, an increasing number of randomized controlled trials (RCTs) looking at ω-3 FA supplemented PN in critically ill adult patients have been performed. Individually, however, they have been insufficiently powered to detect significant results. We therefore decided to systematically review the available evidence and perform a meta-analysis to examine the role of ω-3 FA supplemented PN in comparison with standard care PN in the critically ill adult patient.
METHODS
We undertook our review following a prespecified protocol (see Supplemental Digital Content 1, http://links.lww.com/ CCM/A498).
Search Strategy
Full details of our search strategy can be found in the prespecified protocol (see Supplemental Digital Content 1, http://links. lww.com/CCM/A498). In summary, we performed computerized searches in MEDLINE (1996 to June 2011), EMBASE (1996 to June 2011), and the Cochrane register of controlled trials (June 2011). We searched the abstract proceedings of scientific meetings from 2005 to 2010 for the British Association for Parenteral and Enteral Nutrition, European Society for Clinical Nutrition and Metabolism, and the American Society for Parenteral and Enteral Nutrition.
Inclusion Criteria
Two (A.J.P., A.A.) of us screened all citations and classified them into primary studies, reviewed articles or other. We then retrieved and reviewed independently all primary studies. Primary studies were selected for inclusion if they met the following criteria:
1. Research design: RCT. 2. Population: critically ill adults admitted to the ITU. 3. Intervention: ω-3 FA supplemented PN compared with standard-care PN containing another lipid. 4. Primary outcomes: mortality, hospital LOS, and ITU LOS. 5. Secondary outcomes: new infections, length of mechanical ventilation, adverse events (as defined by the included studies), quality of life, and economic outcomes.
Study authors who evaluated the impact of ω-3 FA on surrogate end points (e.g., cytokine levels) were contacted, and studies included if they could provide relevant outcome data.
Exclusion Criteria
Studies were excluded if:
• ω-3 FA were one of several immune-modulating nutrients given together (given the difficulty in attributing the treatment effects to ω-3 FA).
• ω-3 FA were given for < 24 hrs duration.
• The control intervention did not contain any FA.
In addition, we also excluded studies on elective surgical patients routinely admitted to the ITU.
Dealing With Missing Data
In the case of studies in which data were missing or incomplete, we contacted study authors to request these data. Where the information was unavailable due to data loss or nonresponse, we reported the available results as stated in the trial report. For questions 1-3 and 8-9, possible scores were 0, 1, or 2, for questions 4-7 possible scores were 0 or 1. a Extent to which antibiotics, ventilation, oxygen, and transfusions were applied equally across all groups.
Assessment of Risk of Bias
We assessed the risk of bias in all selected articles in duplicate, independently, using a system (see Table 1 ) previously described (8) . Disagreement was resolved in pairs by consensus.
Analysis
Details of the included studies are presented in Tables 2 and 3 with denominators, means, and standard deviations. We combined data from studies to estimate the common risk ratio (RR) and associated 95% confidence intervals (CI) for death and risk of new infections. We estimated mean difference and 95% CI for LOS. We used the more conservative random effects model due to anticipated heterogeneity. Heterogeneity was expressed as the I 2 statistic where ≥ 50% indicates significant heterogeneity. A conservative analysis was undertaken with all participants randomized to the intervention as the denominator when the total number of participants was available. All meta-analyses are presented as Forest plots with Review Manager (RevMan), Version 5.1, used to perform all statistical analyses.
RESULTS

Literature Search
The literature search identified 12,270 potentially eligible reports. Three non-English language publications were identified: two fully published RCTs in Chinese and one in German published in abstract form only. All were translated, allowing them to be considered for detailed eligibility review. Review of the abstracts (A.J.P., A.A.) resulted in 71 articles for eligibility review.
Study Selection
The results of the eligibility review are shown in Figure 1 using the flow diagram recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) group (9) .
Fourteen RCTs appeared to address the role of ω-3 FA supplemented PN in critically ill adults. Five were excluded for further consideration: one RCT examined the role of ω-3 FA supplemented PN in the first 24 hrs only (10); one RCT was examining PN composed primarily of medium-chain triglycerides in comparison with one containing only longchain triglycerides (11); and three authors (two abstracts and one fully published article) were unable to provide us with relevant outcome data (12) (13) (14) . This left nine RCTs to be included in the primary analysis; six fully published RCTs (15) (16) (17) (18) (19) (20) and three RCTs published in abstract form only (21) (22) (23) . On closer inspection, two of the fully published RCTs by Wang et al (19, 20) , despite the differing number of study participants, were the same trial. We attempted to contact the lead author of the studies by e-mail to clarify this issue but received no response. We have therefore included the data from these studies as it is presented in the two articles, respectively. More precisely, ITU and hospital LOS are presented for 40 patients as published in the Wang 2008 article; and mortality and new infections are presented for 56 patients as published in the Wang 2009 article. Authors of all the abstracts included in the review provided further outcome data following contact via e-mail. Table 2 summarizes the characteristics of the included studies (inclusion and exclusion criteria, details of the participants, and type of publication providing the data). All were singlecenter trials published between 2003 and 2010. Three were in Germany (16) (17) (18) , two in Russia (21, 23) , and one each in China (19, 20) , Portugal (15) , and Romania (22) .
Characteristics of Included Studies
Only one study (18) demonstrated the passage of trial participants through the RCT using the flow diagram recommended by the Consolidated Standards of Reporting Trials group (24) .
One study recruited participants from a medical ITU and therefore with a range of conditions (18) . The remaining trials recruited participants with sepsis (15) (16) (17) , trauma (23), abdominal sepsis (21, 22) , and severe acute pancreatitis (19, 20) . Severity of illness at baseline was objectively defined by all studies using internationally recognized scoring systems.
Clear details of the exact nutritional content of the PN were provided by five studies (15, (18) (19) (20) (21) (22) and are shown in Table 3 . Only two studies objectively defined the reason for starting patients on PN (15, 18) . No study reported failure of enteral nutrition prior to commencement of PN. Nutritional protocols and any deviation from this protocol were absent from all but one report (18) . Where reported, the length of time patients received PN was between 5 and 10 days. The use of enteral nutrition during the intervention period and the subsequent introduction of enteral feeding while receiving PN were only clearly reported by one study (18) .
The dose of ω-3 FA provided to the intervention group was provided by all studies and varied from 0.08 g/kg/d to 0.2 g/ kg/d (see Table 3 ).
Risk of Bias in Included Studies
All studies reported on randomization to treatment allocation but only four studies described proper allocation concealment (15, (18) (19) (20) (21) . Blinding of both participants and treatment providers was reported by only two studies (18) (19) (20) . Three studies reported blinding only the participants (15, 21, 22) . Two studies were open label (16, 17) and one failed to provide sufficient details and was therefore assumed to be nonblinded (23) .
Intention-to-treat analysis was carried out by three studies (16, (18) (19) (20) . After recruitment one study excluded two participants who failed to start PN (15) .
The application of cointerventions, for example, the extent to which antibiotics, ventilation, oxygen, and transfusions were applied, was only partially described by one of the included studies (17) .
No trial reported following up participants beyond this hospital admission, patients' perceived quality of life after discharge, or economic outcomes. On the basis of the meta-analysis from eight studies with 391 participants, it was found that mortality was not different for patients receiving ω-3 FA supplemented PN (RR 0.83; 95% CI 0.57, 1.20; p = 0.32). The test for heterogeneity was nonsignificant (I 2 = 0%; p = 0.96). (continued)
In meta-analysis of five studies with 337 participants, the frequency of new infections was not different for patients receiving ω-3 FA supplemented PN (RR 0.78; 95% CI 0.43, 1.41; p = 0.41). The test for heterogeneity was nonsignificant (I 2 = 51%; p = 0.09).
On the basis of the meta-analysis of six studies with 305 partici pants, there was no difference in ITU LOS for patients receiv ing ω-3 FA supplemented PN (−0.57 days; 95% CI −5.05, 3.90; p = 0.80). The test for heterogeneity was nonsignificant (I 2 = 49%; p = 0.08). On the basis of the meta-analysis of three studies with 117 participants, there was a significant reduction of 9.49 days in hospital LOS for patients receiving ω-3 FA supplemented PN (95% CI -16.51, 2.47; p = 0.008). The test for heterogeneity was nonsignificant (I 2 = 0%; p = 0.37). 
Impact of ω-3 Supplemented PN on Length of Mechanical Ventilation and Adverse Events
DISCUSSION
We investigated the effect of ω-3 FA supplemented PN in the critically ill adult patient on clinically meaningful outcomes. We found no statistically significant results with respect to mortality, infections, and ITU LOS. However, we did find weak evidence that ω-3 FA supplemented PN shortens the hospital LOS.
The evidence for this meta-analysis is weak for a number of reasons. First, relative to other meta-analyses, there were few trials involving ω-3 FA supplemented PN in critically ill adults. Furthermore, these studies were small, single-center studies, with six of the eight trials containing < 50 participants. In addition, the availability of clinically meaningful outcome data was limited. Indeed, our finding of a significant reduction for hospital LOS was based on three studies, totalling 117 participants; uncommon events in a small number of studies are more likely to produce erroneous and/or unstable estimates.
Second, there is a high risk of bias as a result of missing data and the selective reporting of outcomes by the included trials. This is a particularly important point with respect to the duplicate publications by Wang et al. The publication in 2008 provides ITU and hospital LOS data; however, this is absent from the report in 2009, which also includes an additional 16 patients. We attempted to clarify this issue with the corresponding author by e-mail but received no response. Given that these data are included in our only significant finding, we urge readers to be vigilant in their interpretation of this result.
Our significant finding for hospital LOS is worth further consideration. As the weight attributed to each study is determined by the precision of its estimate of effect, which is equal to the inverse of the variance, the study by Grecu et al ends up contributing considerably more due to the huge relative variance of the other included studies. This is important as the study by Grecu et al pertains to the only significant difference. The main influence is the considerably larger standard deviation in the control group compared with the intervention group in the study by Grecu et al, implying that there are cases in the control group with very long LOS dragging the mean upward. As such, we would further reiterate our recommendation that this result be treated with extreme caution.
Other features of the poor methodological quality of the trials are also likely to have biased our findings. Appropriate blinding and clear reporting of allocation concealment are important as failure has been shown to exaggerate treatment effects by up to 26% and 40%, respectively (25) . Intention to treat is important as it preserves randomization, thereby reducing bias, maintaining external validity, and making the results generalizable. In addition, no study reported long term follow-up, failing to account for the prolonged recovery of patients from critical illness.
Individually, the included studies were underpowered to demonstrate a significant effect of ω-3 FA supplemented PN in the critically ill adult patient on outcomes. The advantage of a meta-analysis is that it provides a higher statistical power to detect a significant effect than is possible with any one individual study. However, even the aggregation of insufficiently powered studies may be at the limit to detect a significant result. Given that the upper limit of our 95% CI for mortality was > 1 , we cannot conclude with reasonable confidence that ω-3 FA supplemented PN in the critically ill adult patient is safe (i.e., exclude harm). Given that the conclusions drawn from any metaanalysis can only be as strong as its constituent parts, our work should be viewed as hypothesis generating only.
Meta-analysis of ω-3 FA supplemented PN in patients undergoing elective surgery has suggested benefit, with reductions in the frequency of postoperative infections and ITU and hospital LOS (5) attributed to reductions in the production of proinflammatory eicosanoids and cytokines (26) . Such effects have also been observed in critically ill patients, with suppression of cytokines by endotoxin-stimulated mononuclear cells ex vivo (17) . Given that critically ill individuals and patients undergoing elective surgery both share a SIRS response, it is notable that we failed to show similar benefit. However, dichotomous effects in these two patient groups should perhaps not be unexpected, with the immune response of patients undergoing elective surgery differing from that of critically ill subjects. In critical illness there is a dramatic overamplification of the inflammatory response, together with cellular immune dysfunction; after surgery patients experience less cytokine activation but some suppression of cell-mediated immunity (27) . It is for this reason that we also decided to exclude trials of elective surgical patients routinely admitted to the ITU.
Failure to show benefit may be an issue of timing. A retrospective analysis of patients undergoing abdominal surgery demonstrated lower mortality rates in those who received preoperative ω-3 FA supplemented PN; this was not found in those who received only postoperative supplementation (28) . This suggests the immune-modulating functions of ω-3 FA is greatest at the beginning of the SIRS response. As five of the included studies recruited patients with sepsis/septic shock, it is worth noting that the prompt administration of interventions in sepsis is crucial in improving outcomes (29) . Thus if the "window of opportunity has passed" the ability of ω-3 FA to clinically alter the SIRS response in critical illness may be limited as the excessive cytokine production that characterizes this syndrome is already established.
The dose of ω-3 FA is also worth some consideration. Work on a large cohort of critically ill patients by Heller et al demonstrated a significantly lower rate of infection and ITU and hospital LOS in those patients receiving ≥ 0.05 g/kg/d of ω-3 FA (4). Furthermore, mortality was significantly reduced with doses > 0.1 g/kg/d. Given that the studies included in this review used comparable doses of ω-3 FA, why have we not observed clinical benefit? First, the work by Heller et al must be interpreted with caution due to the lack of randomization and blinding. However, a key problem is the use of the original Simplified Acute Physiology Score II database as a "historical control" group, as the application of Simplified Acute Physiology Score II to more contemporary data may overpredict mortality (30, 31) .
Another salient issue is the choice of lipid emulsion used as the control by the studies. A number of studies used a control lipid emulsion that was lower in ω-6 FA, due to the presence of medium-chain triglycerides. This resulted in the average daily dose of ω-6 FA being reduced, potentially resulting in a control formula that was less inflammatory. This raises the possibility that PNs supplemented with ω-3 FA are not in fact immunomodulating, but less inflammatory. Given that attempts to manipulate the immune system in sepsis/disease with severe SIRS have had little success, we would argue that one needs to be extremely cautious in attempting to alter the inflammatory response of critically ill individuals with such large doses of ω-3 FA. Indeed, the presence or absence of potential complications, for example bleeding, were infrequently reported. If benefits do exist in lowering the ω-6 FA component of lipid emulsions, and it does make biological sense, then if the same benefit can be obtained by substituting a proportion of the ω-6 FA with immunologically inert medium-chain triglycerides, then the need to use large doses of ω-3 FA is questionable. To our knowledge the exact requirement for ω-3 FA in critical illness is unknown. Given that in ischemic heart disease most, if not all, benefit in primary prevention is obtained by consuming 250 to 500 mg of ω-3 FA per day (32) , why have the included studies used such large doses? Future work needs to address these issues, namely: the optimal requirement for ω-3 FA in critical illness; the risk of hemorrhagic complications; and the potential benefits of lipid emulsions rich in medium-chain triglycerides and/or oleic acid over pure soya bean emulsions.
Recently, the benefits of enteral feeds containing ω-3 FA, γ-linolenic acid, and antioxidants in the critically ill patient have been questioned. Meta-analysis of these formulae in adults with acute lung injury had suggested a reduction in mortality, mechanical ventilation, and a shorter ITU LOS (33) . As with the trials included in this review, the trials included in the meta-analysis were small and potentially prone to bias. It is therefore noteworthy that the OMEGA study was stopped early because of a significant increase in mortality, time on a ventilator, longer duration of nonpulmonary organ failure, and ITU LOS (34) . Although it is difficult to attribute these effects to ω-3 FA, this study highlights the problem of relying on meta-analyses of small, underpowered, and methodologically poor RCTs to make evidence-based recommendations.
A strength of our meta-analysis was the comprehensive literature search we undertook. We identified three non-English language RCTs, reducing the possibility of language bias. In addition, we included three conference abstracts of unpublished studies, reducing the possibility of publication bias. We also identified two further conference abstracts but were unable to include these in our meta-analysis as both reported surrogate end points. Contact with leading experts did not yield any unpublished studies.
The main limitation of the study is the heterogeneity of the patient groups. We had originally planned to perform subgroup analyses to explore studies with better methodology to those with lesser methodology and studies evaluating higher ω-3 FA doses compared with those with lower ω-3 FA doses; however, there were insufficient data. We acknowledge that studying an anti-inflammatory intervention in a broad spectrum of critically ill patients increases the likelihood of negative findings. Ideally, we would have performed further subgroup analyses for specific pathologies (e.g., sepsis) in order to try and limit heterogeneity and potential confounding factors, but again this was not possible due to there being insufficient data. At the same time however, it could be argued that the heterogeneous nature of the study population means that our results could be considered generalizable to ITU populations, as has been suggested in other meta-analyses of nutritional interventions in critically ill patients (35) . The considerable statistical heterogeneity we observed for risk of new infection and ITU LOS, although failing to reach statistical significance, reflects the small nature of the included studies, with small studies more susceptible to one outlying observation, which affects the mean and variance, as well as cultural differences in defining critical illness.
In conclusion, there is insufficient evidence to recommend the supplementation of PN in critically ill adult patients with ω-3 FA except as an intervention being investigated in the setting of a RCT. Although ω-3 FA appear to reduce hospital LOS, the poor methodology of the included studies and the absence of other outcome improvements means that this result must be interpreted with caution. In short large, highquality RCTs are required.
